Top 5 Papers
#1
Source: European Commission / AstraZeneca (regulatory) | Authors: AstraZeneca / Daiichi Sankyo — based on DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 | Published: June 2026
Score: 12/20 — Base 8 (regulatory action) + new regulatory standard, first tumor-agnostic HER2 ADC in the EU (+2) + colleague engagement on X (@OncoAlert, @DraMartinezLago) (+2) = 12
For the first time, a HER2-directed therapy can be prescribed in Europe on the basis of a biomarker rather than a tumour's site of origin. The European Commission has approved trastuzumab deruxtecan (T-DXd) as monotherapy for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and have no satisfactory alternative options — making T-DXd both the first HER2-directed therapy and the first antibody-drug conjugate to earn a tumour-agnostic indication in the EU. The decision follows a positive CHMP opinion and rests on HER2-positive (IHC 3+) subgroups pooled across three Phase 2 trials: DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. For GI oncologists the relevance is direct: HER2-overexpressing colorectal and pancreatic cancers fall within the new label, extending an approach already established in the US and more than 15 countries. The practical implication is that standardized HER2 IHC testing now belongs in the workup of refractory GI tumours, since an IHC 3+ result can unlock an active, approved option regardless of primary site.
Post angle: A biomarker, not a primary site, now defines HER2 therapy eligibility in the EU. The European Commission has approved T-DXd as the first tumor-agnostic HER2-directed therapy for previously treated HER2+ (IHC 3+) solid tumors — colorectal and pancreatic included. Time to make HER2 IHC part of the refractory-GI workup. #GIOnc #CRC #HER2 #PrecisionMedicine
#2
Source: Journal of Hepatology | Authors: Peng N, … Yip TCF (senior); territory-wide cohort, Chinese University of Hong Kong | Published: June 26, 2026
Score: 8/20 — Base 6 (Journal of Hepatology) + retrospective / real-world cohort (+1) + biomarker-guided HCC-prevention signal (+1) = 8
Type 2 diabetes is an established risk factor for hepatocellular carcinoma, but whether the trajectory of glycemic control — not just a single reading — predicts liver outcomes has been unclear. This territory-wide Hong Kong cohort followed 294,096 patients with type 2 diabetes and modeled how their HbA1c moved over time. Higher time-weighted average HbA1c was associated with more liver-related events, including HCC and hepatic decompensation (adjusted cause-specific HR 1.12 per 1% increase, p<0.001), and HbA1c variability added further risk. Grouping patients by trajectory, those with a rising HbA1c pattern carried roughly 37% higher risk than those whose HbA1c improved rapidly, and a rapid decrease even from a high baseline mitigated risk. The findings were echoed in a UK Biobank validation. As an observational study it cannot prove that tightening glycemic control prevents liver cancer, but it reframes HbA1c management in diabetics as a potentially modifiable lever for liver health, not solely a cardiometabolic target — and flags the rising-HbA1c patient as someone who may warrant closer hepatic surveillance.
Post angle: Glycemic control may be a liver-cancer lever, not just a cardiometabolic one. Hong Kong cohort, n=294,096 with T2DM: higher time-weighted HbA1c tracked with more liver-related events incl. HCC (aCSHR 1.12 per 1%, p<0.001), and a rising trajectory carried ~37% higher risk than rapidly improving. Watch the rising-HbA1c patient. #HCC #LiverCancer #GIOnc
#3
Source: Endoscopy | Authors: Codesido-Prado L, … Cubiella J (senior); Galician CRC screening programme, Spain (multicenter) | Published: June 28, 2026
Score: 8/20 — Base 5 (Endoscopy) + randomized controlled trial (+3) = 8
AI-based computer-aided detection (CADe) has been promoted as a way to raise adenoma detection at colonoscopy, but its benefit in real-world, high-quality programs remains contested. This population-based randomized trial within the Galician colorectal cancer screening program enrolled 4,824 surveillance colonoscopies, randomizing to CADe-assisted versus standard examination. The primary endpoint — adenoma detection rate — did not differ overall: 57.4% with CADe versus 58.8% without (adjusted risk ratio 1.02, 95% CI 0.95–1.10). The signal of benefit was confined to lower-performing endoscopists (those with baseline ADR below 54.5%), where CADe lifted detection (aRR 1.15); high performers gained nothing. Strikingly, a second randomized trial from the same investigators this week — PolyDeep Advance 3 (n=854 in a screening setting) — was also negative for ADR. Together they argue that CADe is not a universal ADR booster: in programs that already perform well, the marginal value is small, and the technology's role may be best framed as a leveling tool for less-experienced operators rather than a blanket standard.
Post angle: AI colonoscopy meets a reality check. Galician population-based RCT, n=4,824 surveillance colonoscopies: CADe did NOT raise adenoma detection overall (57.4% vs 58.8%, aRR 1.02) — benefit only in lower-performing endoscopists. A second RCT the same week (PolyDeep, n=854) was also negative. CADe may level operators, not lift everyone. #CRC #Colonoscopy #GIOnc
#4
Source: Cancer Discovery | Authors: MD Anderson Cancer Center & Memorial Sloan Kettering (incl. Kopetz, Cercek, Diaz); multicenter | Published: June 26, 2026
Score: 7/20 — Base 6 (Cancer Discovery) + biomarker / mechanism (intratumoral microbiome–interferon axis in dMMR GI cancers) (+1) = 7
Why some gastrointestinal tumours respond dramatically to immune checkpoint blockade while others do not remains incompletely explained, and this MD Anderson/MSKCC collaboration points to the microbes living inside the tumour. Profiling intratumoral microbial burden (ITMB) across cancer types, the authors found the immunologic effects were concentrated in colorectal and gastric cancer: high ITMB correlated with active interferon signaling and improved outcomes in advanced disease. Mismatch-repair-deficient (dMMR) tumours carried higher microbial burden than proficient tumours, and in a dMMR rectal cohort with a 100% remission rate on checkpoint blockade, tumour microbes and microbe-containing mast cells increased on treatment. Mechanistically, depleting microbes in mouse models impaired checkpoint-blockade efficacy and downregulated interferon-stimulated genes, while restoring interferon-response-gene expression rescued the response. The work is preclinical and correlative in its human components, so it does not yet change practice — but it offers a compelling biological thread linking the dMMR phenotype, the tumour microbiome, and interferon-driven immunogenicity, and hints that the microbiome could become both a biomarker and a therapeutic handle in GI immuno-oncology.
Post angle: The bugs inside the tumor may help explain why dMMR GI cancers respond to IO. MD Anderson + MSKCC: high intratumoral microbial burden drives interferon signaling and checkpoint-blockade response, concentrated in colorectal & gastric cancer and highest in dMMR tumors; depleting microbes blunted IO efficacy in models. A microbiome biomarker — and maybe a handle. #CRC #GastricCancer #GIOnc
#5
Source: Clinical & Experimental Metastasis | Authors: Vitale E, … Brandi G (senior); multicenter (Italy/Brazil/Turkey) | Published: June 29, 2026
Score: 7/20 — Base 5 (other peer-reviewed journal) + meta-analysis (+2) = 7
Adding a PD-(L)1 inhibitor to gemcitabine and cisplatin is now first-line standard for advanced biliary tract cancer on the strength of TOPAZ-1 (durvalumab) and KEYNOTE-966 (pembrolizumab), but clinicians still ask what that immunotherapy layer costs in tolerability. This systematic review and meta-analysis pooled the two pivotal trials, encompassing 1,754 patients with advanced biliary tract cancer, to compare the safety of chemoimmunotherapy against chemotherapy plus placebo. The risk of most treatment-emergent adverse events did not differ significantly between the chemoimmunotherapy and chemotherapy-alone arms, supporting the conclusion that the survival gains seen with checkpoint inhibition come without a meaningful increase in overall toxicity. The analysis is restricted to safety endpoints and adds no new efficacy data, and pooling only two trials limits granularity around immune-related events. Still, for a disease where treatment tolerance is a real concern, it provides a tidy, reassuring confirmation that the now-standard chemo-IO backbone is as tolerable as chemotherapy alone — useful when counseling patients about what to expect from first-line therapy.
Post angle: Does adding immunotherapy to chemo in biliary cancer cost tolerability? Meta-analysis of TOPAZ-1 + KEYNOTE-966 (n=1,754 advanced BTC): adding a PD-(L)1 inhibitor to gem/cis did NOT significantly raise overall treatment-emergent adverse events vs chemo alone. The survival gains of the chemo-IO standard don't come at a meaningful safety cost. #Cholangiocarcinoma #GIOnc
Additional Papers of Interest
-
Endoscopy — a second negative CADe randomized trial from the Galician group this week: among 854 patients undergoing colonoscopy after a positive FIT or for surveillance, PolyDeep-assisted colonoscopy did not improve adenoma detection (60.8% vs 57.7%, aRR 1.05, 95% CI 0.94–1.17), with no significant difference in serrated, advanced-adenoma or polyp detection — reinforcing that computer-aided detection adds little ADR benefit in already well-performing screening programs.
-
Supportive Care in Cancer — in 50 patients with colorectal cancer, GIST or HCC starting regorafenib or sorafenib, adding a prophylactic hydrocolloid dressing to standard moisturizing cut grade ≥2 hand-foot skin reaction on the soles from 50% to 20% (p<0.0001) and lengthened time to HFSR (HR 0.32) — a simple, low-cost supportive-care measure to keep patients on dose-limiting multikinase inhibitors used across GI cancers.
-
La Medicina del Lavoro — pooling 18 studies (20 risk estimates), cadmium exposure was associated with increased pancreatic cancer risk (RR 1.69, 95% CI 1.28–2.22), with the most consistent signal for occupational exposure (RR 1.38) and higher risk in men; heterogeneity and limited dose-response data temper causal inference but add to the environmental-risk picture for a lethal GI malignancy.
-
Occupational and Environmental Medicine — a contrasting environmental read: across 29 publications, occupational hexavalent-chromium exposure showed no convincing association with pancreatic (incidence RR 1.04) or small-intestine cancer, with only weak mortality signals — a reminder that not every workplace carcinogen translates into measurable GI-cancer risk.
Back to all digests